Genotypic and Phenotypic Correlates of Resistance to Aspirin

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

190 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-12-31

Study Completion Date

2011-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study seeks to identify genomic markers associated with aspirin resistance.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PPARGC1β and CNTN4 Genotype Aspirin Study

NCT02970604

Cardiovascular Diseases

UNKNOWN PHASE4

GM03 - Platelet RNA Signatures of Aspirin

NCT05278637

Platelet Aggregation Inhibitors Aspirin Ticagrelor +1 more

COMPLETED EARLY_PHASE1

Aspirin and Thienopyridine Resistance in Peripheral Arterial Disease

NCT03174990

Peripheral Arterial Disease Clopidogrel, Poor Metabolism of

COMPLETED

Aspirin Resistance in Coronary Artery Disease

NCT00753935

Coronary Artery Disease

COMPLETED EARLY_PHASE1

Improving Aspirin Use Among Adults at Risk for Cardiovascular Disease (CVD)

NCT00981032

Cardiovascular Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Not desired

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Platelet Dysfunction Due to Aspirin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Aspirin

All subjects took 7-10 days of 81 mg aspirin

Group Type OTHER

aspirin

Intervention Type DRUG

aspirin 81mg, 7-10 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

aspirin

aspirin 81mg, 7-10 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Volunteers 40 to 80 years old willing to sign consent and take 81 mg of aspirin for 7 - 10 days and return for laboratory testing.

Exclusion Criteria

* Patient requiring more than 81 mg aspirin daily
* Known GI bleeding attributed to ASA
* Active peptic ulcer disease or history within the last year
* Known aspirin allergy
* Current use of:

* warfarin,
* heparin,
* NSAIDs (except aspirin),
* clopidogrel,
* dipyridamole,
* fish-oil/omega 3 supplements,
* Women of childbearing potential who are pregnant, planning to become pregnant or nursing.

Minimum Eligible Age

40 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes